Sugi Predict

Sugi Predict / Compounds / SCHEMBL193719

SCHEMBL193719

SCHEMBL193719

N#Cc1c[nH]c(-c2ccccc2F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRG2 P18507 1/20 0.40
▸ GABRB3 P28472 1/20 0.40
▸ GABRA5 P31644 1/20 0.40
▸ GABRA3 P34903 1/20 0.40
▸ CHUK O15111 1/20 0.39
▸ CCNE2 O96020 1/20 0.38
▸ EGFR P00533 1/20 0.38
▸ CDK1 P06493 1/20 0.38
▸ CDK4 P11802 1/20 0.38
▸ SRC P12931 1/20 0.38
▸ CCND1 P24385 1/20 0.38
▸ CCNE1 P24864 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ KDR P35968 1/20 0.38
▸ CCNA1 P78396 1/20 0.38
▸ PTK2 Q05397 1/20 0.38
▸ NISCH Q9Y2I1 1/20 0.38
▸ AR P10275 1/20 0.37
▸ CYP11B1 P15538 2/20 0.36
▸ CYP11B2 P19099 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29519961 1.00 GABRG2 (0.40) GABRG2GABRB3GABRA5GABRA3CHUK
SCHEMBL23067647 0.86 POLB (0.35) GABRG2GABRB3GABRA5GABRA3CHUK
SCHEMBL20952245 0.85 CHUK (0.36) GABRG2GABRB3GABRA5GABRA3CHUK
SCHEMBL193781 0.79 LRRK2 (0.41) NISCHARCYP11B1CYP11B2HTR1A
SCHEMBL29815621 0.79 LRRK2 (0.41) NISCHARCYP11B1CYP11B2HTR1A
SCHEMBL10513084 0.74 AR (0.34) AR
SCHEMBL195094 0.74 CYP19A1 (0.49) GABRG2GABRB3GABRA5GABRA3HTR1A
SCHEMBL10502772 0.73 DYRK1A (0.38) KDRHPGDKDM4EALDH1A1GLA
SCHEMBL29011672 0.73 IDO1 (0.34) CCNE2CCNE1CDK2NISCHADORA1
SCHEMBL6248864 0.73 MAPT (0.40) GABRG2GABRB3GABRA5GABRA3NISCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025098443-A1 METHOD FOR PREPARING 1-[5-(2-FLUOROPHENYL)-1-{[3-(3-METHOXYPROPOXY)PHENYL]SULFONYL}-1H-PYRROL-3-YL]-N-METHYLMETHYLAMINE AND HYDROCHLORIDE THEREOF 江苏柯菲平医药股份有限公司 2025-05-15 — — WO claimed
CN-113511995-B Preparation method of 5- (2-fluorophenyl) -1H-pyrrole-3-formaldehyde 四川科伦药物研究院有限公司 2024-07-09 — — CN claimed
CN-118108651-A Preparation method of 5- (2-fluorophenyl) -1H-pyrrole-3-formaldehyde 中山奕安泰医药科技有限公司 2024-05-31 — — CN claimed
CN-118108652-A Preparation method of 5- (2-fluorophenyl) -1H-pyrrole-3-carbonitrile 中山奕安泰医药科技有限公司 2024-05-31 — — CN claimed
CN-113549054-B Vonoprazan fumarate intermediate and preparation method thereof 鲁南制药集团股份有限公司 2024-03-15 — — CN claimed
CN-117247344-A Preparation method of voronoi intermediate 5- (2-fluorophenyl) -1H-pyrrole-3-carbonitrile 安徽迪合永欣药业有限公司 2023-12-19 — — CN claimed
CN-117030876-A Method for detecting related substances of Fu Nuola raw starting material of fumaric acid 山东新华制药股份有限公司 2023-11-10 — — CN claimed
CN-114853728-B Vonopraz fumarate tablet and preparation method thereof 四川制药制剂有限公司 2023-11-07 — — CN claimed
CN-116332821-A Preparation method of 5- (2-fluorophenyl) -1H-pyrrole-3-carbonitrile 杭州国瑞生物科技有限公司 2023-06-27 — — CN claimed
CN-114853728-A Vonola fumarate tablet and preparation method thereof 四川制药制剂有限公司 2022-08-05 — — CN claimed
CN-113549054-A Vonoprazan fumarate intermediate and preparation method thereof 鲁南制药集团股份有限公司 2021-10-26 — — CN claimed
CN-113511995-A Preparation method of 5- (2-fluorophenyl) -1H-pyrrole-3-formaldehyde 四川科伦药物研究院有限公司 2021-10-19 — — CN claimed
CN-108503621-B Preparation method of vonoprazan fumarate 上海中拓医药科技有限公司 2021-09-14 — — CN claimed
CN-112194607-A Synthetic method of 5- (2-fluorophenyl) -1H-pyrrole-3-formaldehyde 河北科博莱特医药科技有限公司 2021-01-08 — — CN claimed
CN-108503621-A A kind of preparation method of Vonoprazan fumarate 上海中拓医药科技有限公司 2018-09-07 — — CN claimed
EP-2765130-B1 Intermediates for use in a process of producing pyrrole compounds TAKEDA PHARMACEUTICALS CO (JP) 2017-07-26 — — EP claimed
US-12351553-B2 Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-07-08 — — US disclosed
WO-2025098443-A1 METHOD FOR PREPARING 1-[5-(2-FLUOROPHENYL)-1-{[3-(3-METHOXYPROPOXY)PHENYL]SULFONYL}-1H-PYRROL-3-YL]-N-METHYLMETHYLAMINE AND HYDROCHLORIDE THEREOF 江苏柯菲平医药股份有限公司 2025-05-15 — — WO disclosed
US-20110306769-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-15 — — US disclosed
US-20110306769-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12351553-B2 Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation CYP51A1, PAH, HPD GABRG2 2527/4885GABRB3 1607/4885GABRA5 1398/4885
US-20110306769-A1 PROCESS FOR PRODUCING PYRROLE COMPOUND DHPS, STS, HPD GABRG2 1838/4885GABRB3 1965/4885GABRA5 1506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.